Reata Pharmaceuticals Stock Price. Everything You Need To Know About The Reata Pharmaceuticals Stock!
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. The company is headquartered in Plano, Texas and currently employs 321 full-time employees. The company went IPO on 2016-05-26. The firm concentrates on small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases. Its lead programs are omaveloxolone in a rare neurological disease called Friedreich’s ataxia (FA) and bardoxolone in rare forms of chronic kidney disease (CKD). Both of its lead product candidates activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation. The company possesses worldwide rights to develop, manufacture, and commercialize omaveloxolone, bardoxolone, and other Nrf2 activators, excluding certain Asian markets for bardoxolone in certain indications. In addition, the Company is developing cemdomespib, the lead product candidate from its Hsp90 modulator program, in neurological indications. The firm has three pipeline programs for CKD.
Reata Pharmaceuticals Stock Price. Everything You Need To Know About The Reata Pharmaceuticals Stock! performance
- Employees 321
- Company HQ Plano
- Website https://www.reatapharma.com/
- Asset Type
- Market Capitalization 0
- Earnings Per Share
- Dividends Per Share
- Dividend Date
- Quarterly Earnings Growth
If you’re an investor from Malaysia, Thailand, Indonesia, or Vietnam and are looking to invest in the stock market, one stock that deserves your attention is Reata Pharmaceuticals. Reata Pharmaceuticals is a cutting-edge biopharmaceutical company that focuses on developing novel therapies to treat severe diseases. With a strong pipeline of potential breakthrough drugs, this stock has the potential for significant growth in the future. But how can you invest in Reata Pharmaceuticals? Fortunately, Zorion is here to help. As an investment platform, Zorion offers users from these countries the opportunity to invest in real US stocks, including Reata Pharmaceuticals. With investment insights and recommendations, as well as access to educational materials, Zorion ensures that retail investors can make informed decisions about their investment in Reata Pharmaceuticals. So if you’re interested in investing in this promising stock, let Zorion guide you on your investment journey.
